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ABSTRACT: Background. The purpose of this study was to use time
trade-off to assess the factors influencing patients’ decisions in
advanced laryngeal cancer. Time trade-off is a well-established method
of assessing how individuals value a particular health state.
Methods. We developed vignettes depicting life after chemoradiotherapy
or laryngectomy. One hundred fourteen participants ranked them,
assigned utility values, and rated the importance of survival on treatment
choice.
Results. Chemoradiotherapy was preferred by 62% and laryngectomy by
38%. Chemoradiotherapy optimal outcome had the highest mean utility
value (0.64) followed by total laryngectomy optimal outcome (0.56). Total
laryngectomy poor outcome (0.33) was equivalent to chemoradiotherapy
poor outcome (0.32).The average survival advantage required for a par-
ticipant to change their preferred choice was 2.1 years.
Conclusion. The functional treatment outcome had a greater effect on
health state utility values than treatment modality. In many individuals,
larynx conservation may not be the primary consideration in treatment
preference. VC 2015 Wiley Periodicals, Inc. Head Neck 00: 000–000,
2015
KEY WORDS: chemoradiotherapy, head and neck neoplasms, laryn-
geal neoplasms, laryngectomy, larynx
INTRODUCTION
Treatment options for locally advanced laryngeal cancer
have changed radically over the past 2 decades.1–3 In
1981, when total laryngectomy was the standard of care,
McNeil et al4 published a landmark study scrutinizing the
trade-off between quantity and quality of life faced by
patients diagnosed with locally advanced laryngeal can-
cer. At the time of its publication, the majority of patients
undergoing a total laryngectomy would have no voice
after the procedure, or would produce a voice using an
electrolarynx, which gives a characteristically artificial or
robotic sound. The premise of the utility analysis McNeil
presented to her 37 healthy volunteers was that radiother-
apy was associated with a poorer survival, but a better
voice outcome, whereas a laryngectomy achieved an
improved survival at the expense of an artificial
voice. The conclusion that survival may not be the most
important outcome for all patients has been cited over
600 times in subsequent literature, but is typically mis-
quoted to support the move toward primary nonsurgical
therapy of locally advanced laryngeal cancer.5
McNeil’s demonstration that not everyone valued sur-
vival at any price became incorporated into clinical man-
agement. Since McNeil’s study, large randomized
controlled trials have been interpreted as showing that radi-
cal courses of chemoradiotherapy offered equivalent sur-
vival to total laryngectomy.6,7 As a result, concurrent
chemoradiotherapy has become accepted as the first-line
management for locally advanced laryngeal cancer, with
total laryngectomy relegated to a salvage intervention. This
practice has recently been questioned, however, because of
concerns about the high complication rate, the need for
excision of necrotic larynx, and, most worryingly, the pos-
sibility that overall survival from advanced laryngeal can-
cer has been adversely affected.1,8 This is the first study to
revisit McNeil’s seminal time trade-off experiment using
modern treatment outcomes. We aimed to reevaluate the
preferences of a population demographically matched to
the head and neck cancer population and to assess the
importance of survival on treatment choice.
MATERIALS AND METHODS
Participants
Participants were aged over 45 years, with no history
of head and neck cancer. All participants were able to
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speak or read English. Patients were recruited from 2
cohorts: healthy volunteers and patients with chronic
obstructive pulmonary disease (COPD). Patients with
COPD were recruited from a registry at the Sir William
Leech Respiratory Clinical Trials Unit, Freeman Hospital,
Newcastle upon Tyne, UK, and outpatient clinics. These
patients were recruited as they have similar characteristics
to the head and neck cancer population; for example age,
smoking status, comorbidity profile, and socioeconomic
class. Healthy volunteers were recruited from diverse
sources to ensure laryngeal cancer population age/sex rep-
resentation, including from VOICENorth (a registry held
by the Clinical Aging Research Unit at Newcastle Univer-
sity), control registries at the Sir William Leech Respira-
tory Clinical Trials Unit, spouses of patients with COPD,
and a public advertisement.
All participants were interviewed between January
2011 and December 2012, after they provided written
informed consent. The study was approved by both the
Newcastle University Ethics Committee and Newcastle
upon Tyne Regional Ethics Committee and adopted onto
the UK National Institute for Health Research portfolio
(UKCRN ID 10996).
Four health state descriptors were developed depicting
the treatment process and outcome for chemoradiotherapy
optimal outcome, chemoradiotherapy with complications,
total laryngectomy optimal outcome, and total laryngec-
tomy with complications. The health state vignettes were
initially compiled by members of the study team (J.B.
and D.H.) using extensive literature review and clinical
experience. They were then shown to surgeons, oncolo-
gists, speech and language therapists, and clinical nurse
specialists and edited based on the feedback received.
Finally, the health state vignettes were shown to patients
who had undergone treatment (surgical and nonsurgical)
to determine whether they were a true reflection of life
after treatment for head and neck cancer and again edited
based on the feedback. Audio and video recordings of
speech after chemoradiotherapy and of tracheo-
esophageal speech after total laryngectomy were devel-
oped during pilot work to use alongside the vignettes,
together with pictures of a tracheal stoma, skin changes
because of radiotherapy, and a gastrostomy.
First, participants were presented with the audiovisual
information on the process and outcomes of treatment
using the videos, recordings, and pictures developed dur-
ing the pilot work together with a standardized explana-
tion given by the interviewer. The 4 health states were
then introduced and participants were asked to carry out
3 exercises. In exercise 1, participants ranked the 4 avail-
able health states alongside their own health from most to
least desirable. In exercise 2, participants were offered a
choice between alternative 1 (to remain in one of the
health states for 10 years) and alternative 2 (to retain nor-
mal health, but with a decreased survival [x years]). X
was varied until the respondent became indifferent
between the 2 alternatives, at which point the utility value
for that health state was derived. For example, a partici-
pant who felt 10 years with a laryngectomy was equiva-
lent to 7 years in their normal health state yields a
laryngectomy utility value of 7/105 0.7. Each of the 4
health states was presented similarly and in a random
order to control for order of study bias.9 During exercise
3, the participants were asked again which of the 2 opti-
mal outcome health states they would prefer: total laryn-
gectomy optimal outcome, or chemoradiotherapy optimal
outcome. The years of survival associated with the non-
preferred option were then increased (using a similar
technique to the time trade-off exercise) in order to deter-
mine the number of years of survival advantage, if any,
that would lead to a change in their decision.
Statistical analysis
We calculated that 70 participants would be needed to
detect a difference in mean utility scores of 0.1 on the
interval scale, in which a5 0.05, power5 80%, and
SD5 0.25 were around the mean score. The minimum
meaningful utility value difference is difficult to define,
however, a difference of 0.1 is considered to be clinically
significant.9 Differences in health utilities ascribed to var-
ious health states were investigated using mixed models
with variation within participants (each participant rated a
number of health outcomes), and variation between par-
ticipants included as random effects. Participant type
(patient or control), treatment modality (chemoradiother-
apy or total laryngectomy), and treatment outcome (opti-
mal or poor) were included as fixed effects. To test
whether the difference between optimal and poor out-
comes differed between treatment modalities, an interac-
tion between treatment modality and treatment outcome
was included in the model. Models were fitted using the
“xtreg” procedure in Stata version 12 using maximum
likelihood estimation.
RESULTS
A total of 114 participants took part in the study, includ-
ing 63 patients with COPD and 51 healthy volunteers. The
average age of participants was 67.3 years (Table 1). One
participant was able to complete only the ranking exercise.
The chemoradiotherapy optimal outcome was chosen as
the preferred health state by 71 of 114 participants (62%).
TABLE 1. Sociodemographic descriptors of participants.
No. of participants %
Participant type
COPD patient 63 45
Control 51 55
Sex
Male 56 49
Female 58 51
Home situation
Alone 42 39
Family 66 61
Smoking status
Nonsmoker 37 32
Ex-smoker 57 50
Smoker 20 18
Educational level
Secondary school 51 47
Certificate/diploma 41 38
University 16 15
Abbreviations: COPD, chronic obstructive pulmonary disease.
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Total laryngectomy with good outcome was the preferred
health state for 43 of 114 (38%; Table 2). The majority
of patients (72 of 114; 63%) ranked chemoradiotherapy
with complications as their least preferred health state.
A utility value is a value between zero and 1, in which
zero is assumed to be equated to “being dead” and 1 is
equated with “full/normal health.”10 The difference in
utility value considered to be clinically significant is 0.1.
The observed distributions of utility scores for each treat-
ment modality and outcome are shown in Figures 1 and
2. The utility associated with different outcomes was
investigated by fitting a series of mixed models. The
interaction between treatment modality (chemoradiother-
apy vs total laryngectomy) and treatment outcome (opti-
mal vs poor) was highly significant (p< .001).
When all patients’ data were combined, chemoradio-
therapy optimal outcome had the highest mean utility
value (0.64; 95% confidence interval [CI]5 0.58–0.69)
followed by total laryngectomy optimal outcome (0.57;
95% CI5 0.51–0.63; Figure 2). The mean difference
between total laryngectomy optimal outcome and chemo-
radiotherapy optimal outcome was 0.07 (95% CI5 0.02–
0.12). However, when the utility values for optimal out-
come and outcome with complications health states were
combined for each of the treatment modalities, there was
minimal difference between total laryngectomy and che-
moradiotherapy (mean, 0.03; 95% CI520.01 to 0.06).
When patients were divided according to their ranking in
exercise 1, those who ranked total laryngectomy the high-
est assigned a higher utility value to total laryngectomy
optimal outcome than chemoradiotherapy optimal out-
come (0.59 vs 0.53; Table 3). Total laryngectomy poor
outcome was not significantly different to chemoradio-
therapy poor outcome with a difference of 0.02 (95%
CI520.06 to 0.3). The difference between optimal out-
come and outcome with complications was greater for
chemoradiotherapy (0.32; 95% CI5 0.27–0.37) than for
total laryngectomy (0.23; 95% CI5 0.19–0.28).
There was a large variation in the survival advantage
required to switch participant choice from their preferred
treatment to their nonpreferred treatment modality.
Thirty-six participants (32%) would not change their ini-
tial preference for any survival advantage. Of the 68%
willing to consider a change, the mean survival advantage
required to change was 2.5 years (range, 6 months to 5
years). A higher ratio of patients who ranked total laryn-
gectomy as their first choice (37%) would never change
TABLE 2. Summary of how favorably each health state was ranked.
Rank ordering (%)*
Health state 1 2 3 4
TL good 43 (37.7) 51 (44.7) 23 (20.2) –
TL poor – 16 (14.0) 53 (46.5) 42 (36.8)
CRT good 71 (62.3) 26 (22.8) 16 (14.0) –
CRT poor – 21 (18.5) 22 (19.3) 72 (63.2)
Abbreviations: TL, total laryngectomy; CRT, chemoradiotherapy.
* The most preferable health state is ranked as 1 and the least preferable is ranked as 4.
FIGURE 1. Utility values assigned by each individual participant for total laryngectomy and chemoradiotherapy optimal outcome and outcome with
complications. TL, total laryngectomy; CRT, chemoradiotherapy. [Color figure can be viewed in the online issue, which is available at wileyonlineli-
brary.com.]
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their decision compared to those who ranked chemoradio-
therapy as the first choice (24%).
DISCUSSION
This is the first study to critically appraise treatment
choices for the locally advanced laryngeal cancer popula-
tion demographically matched to new attenders at a head
and neck cancer clinic. The chemoradiotherapy optimal
outcome was the most preferred health state with 62% of
participants ranking it highest, although a significant
minority of participants (38%) would rank total laryngec-
tomy with optimal outcome first. The functional outcome
of treatment was a greater determinant of the value of
assigned health state utility than treatment modality. Che-
moradiotherapy had the larger difference between optimal
outcome and outcome with complications and, as a result,
63% of participants ranked chemoradiotherapy outcome
with complications as the least preferred option. If the
utility values for both good and bad outcomes were com-
bined for each modality, there was no significant differ-
ence between them. In addition, on average, those who
ranked a treatment modality as preferable (in exercise 1)
subsequently assigned the associated health state a higher
utility value. Participants held their preferences strongly,
with almost a third of participants adhering to their origi-
nal treatment choice, despite being offered a significant
survival advantage for their nonpreferred option. Those
who chose total laryngectomy as their first option were
more likely to adhere to this option than those who chose
chemoradiotherapy.
The desire to preserve the larynx has driven clinical
trial design for 25 years, under the assumption that this is
a priority for patients. Our data question this central prin-
ciple, and suggest that the potential trade-offs that may be
required to preserve the larynx are not acceptable to all
patients. Indeed, it was recognized recently by the Inter-
national Head and Neck Scientific Group that “avoiding
surgery at the expense of losing the ability to swallow
and/or speak with other modes of therapy cannot be con-
sidered a success,”11 leaving the head and neck cancer
community to ponder whether the pendulum has swung
too far in favor of chemoradiotherapy.12
Various authors have used expected utility theory to
address the question of treatment choice in locally
advanced laryngeal cancer. Laccourreye et al13 recently
asked 309 otolaryngology patients the reduction in cure
rate that they would accept in order to preserve their lar-
ynx. The presented trade-off, however, was predicated on
a reduced chance of cure from nonsurgical management,
which was unacceptable to 24.6% of participants. In this
study, the authors described the health states according to
modality but did not attempt to characterize the quality of
the options presented or define the presence or absence of
complications. Jalukar et al14 rated the importance of out-
come with regard to specific aspects of quality of life
(breathing, eating, speech, etc.), but these were not
modality specific. The study by van der Donk et al15 used
time trade-off to assess T3 laryngeal cancer outcomes and
reported utility values that were similar to our own (0.73
for radiotherapy and 0.66 for surgery). In the van der
Donk et al15 study, brief favorable outcome descriptors
were presented; in the present study these descriptors
were accompanied by audio and visual information.
There is disagreement about which population provides
the best valuation of a health state. Patients who have
experience with a health state may be thought to provide
the most “accurate” assessment of its quality, but tend to
rate it higher than those who have not.16 The United
Kingdom’s National Institute for Health and Clinical
Excellence17 clearly states that the health state descriptors
should be informed by patients and valued by a represen-
tative sample of the population. In 1981, McNeil’s sample
population consisted of firemen and middle managers,
which arguably did not sufficiently represent patients
with head and neck cancer.4 The present study partici-
pants match patients who present as new attenders to a
head and neck cancer clinic. Health state descriptors were
developed in conjunction with patients experiencing the
health state and health professionals involved in the care
of these patients, and our sample population was demo-
graphically matched to the head and neck cancer
population.
TABLE 3. Average utility values assigned using time trade-off, divided by
patients ranking total laryngectomy and those ranking chemoradiother-
apy the highest in exercise 1.
CRT
optimal
outcome
CRT outcome
with
complications
CRT
optimal
outcome
CRT outcome
with
complications
Ranked CRT first 0.70 0.37 0.55 0.34
Ranked TL first 0.53 0.22 0.59 0.22
All participants 0.64 0.31 0.57 0.33
Abbreviations: CRT, chemoradiotherapy; TL, total laryngectomy.
FIGURE 2. Box and whisker plots of health utility scores for each
treatment modality and outcome. The horizontal line in the center
of each box plot corresponds to the median utility, the upper and
lower edges of the box correspond to the 75th and 25th percen-
tiles, respectively, and the whiskers indicate the distribution of
the upper and lower quartiles. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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Shared decision-making allows the sharing of informa-
tion between the patient and the clinician. The clinician
provides information about the risks and benefits of the
treatment options, and the patient provides information
about their values and preferences.18 We have demon-
strated that participants with similar age and educational
level to those attending the head and neck cancer clinic
are capable of processing complex information about
treatment choices and expressing strong preferences as a
result. Participants ranked treatment options and weighed
up a complex (albeit hypothetical) treatment choice: the
resultant choice had a significant effect on the utility
value assigned to health states.
Thirty years ago, McNeil et al4 concluded that survival
may not be the priority for all patients treated. Our con-
clusion has an important difference: larynx preservation
may not be the priority of all patients and therefore
patient preference should be a central part of the treat-
ment selection. Our study has demonstrated that the qual-
ity of the treatment outcome had a more significant effect
on the utility value assigned to a health state than the
modality of treatment. Research is therefore required on
the relative proportion of good versus poor outcome as
this emerges as a key consideration for appropriate patient
participation in decision-making.
APPENDIX
HEALTH STATE: Total laryngectomy optimal outcome
 Voice
 You will lose your normal speech.
 You will produce a voice by putting a finger on the hole in your neck, pushing air out through your mouth.
 Temporary side effects
 Pain after operation will be well controlled with painkillers.
 Radiotherapy after the operation will give you burned red skin in the neck.
 After the operation, you will have difficulty swallowing, this will improve gradually.
 Permanent side effects
 You will have a changed appearance – there will be a hole in the neck (covered by a speech button).
 Your sense of smell and taste will be affected or lost.
 You will produce some mucus from the hole in the neck.
 Function
 In time, you will be able to eat a near normal to normal diet.
 You are likely to have a relatively good voice using the speech valve.
HEALTH STATE: Total laryngectomy outcome with complications
 Voice
 You will lose your normal speech.
 You will produce a voice by putting a finger on the hole in your neck, pushing air out through your mouth.
 Temporary side effects
 Pain after operation will be well controlled with painkillers.
 Radiotherapy after the operation will give you burned red skin in the neck.
 After the operation, you will have difficulty swallowing, this will improve gradually.
 Permanent side effects
 You will have a changed appearance – there will be a hole in the neck (covered by a speech button).
 Your sense of smell and taste will be affected or lost.
 You will produce some mucus from the hole in the neck.
 Function
 You may need to stick to a softened diet, because of swallowing difficulties.
 You may struggle to use the speech valve or to produce a good voice, if so, you may need to find other ways to commu-
nicate like gestures or writing things down.
 Complications
QUALITY VS QUANTITY OF LIFE IN LARYNGEAL CANCER
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 The wound in your neck may not heal correctly.
 There might be irritation and crusting of the hole in the neck.
 Depending on the severity of complications, you may need further operations on your neck.
HEALTH STATE: Chemoradiotherapy optimal outcome
 Voice
 You will be able to speak normally, but your voice will sound weaker and hoarse.
 Temporary side effects
 The treatment will make you feel fatigued and ill.
 You will experience difficulty and pain while swallowing and, therefore, may need a feeding tube through the nose or
into the stomach.
 Red skin reaction and swelling of the neck may be painful.
 Permanent side effects
 You will have a dry mouth.
 Your ability to taste food might change.
 Function
 You will be able to have a near normal diet.
 Your voice will be different than before.
HEALTH STATE: Chemoradiotherapy outcome with complications
 Voice
 You will be able to speak normally, but your voice will sound weaker and hoarse.
 Temporary side effects
 The treatment will make you feel sick, fatigued, and ill, which may cause you to be admitted to the hospital.
 You will experience difficulty and pain while swallowing and, therefore, will need a feeding tube through the nose
or into the stomach.
 You will have a painful skin reaction and swelling of the neck, which may need regular morphine medication.
 Permanent side effects
 You will have a very dry mouth, which will bother you during the biggest part of the day.
 Your ability to taste food will change or be lost.
 Function
 Swallowing will cause problems, because liquids may go down the wrong way and you may be advised to have
nothing by mouth. This means you will be fed by a feeding tube.
 You might struggle to be heard when there are more people in a room.
 Complications
 You will have thick secretions in your throat that are difficult to clear and may cause trouble breathing.
 A feeding tube in the stomach (percutaneous endoscopic gastrostomy), this is likely to be permanent.
 There will be 1 or 2 large, painful ulcers in the mouth.
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